#United States #Dublin #Jazz Pharmaceuticals #Epidiolex #Xywav

Jazz Pharmaceuticals Financial Results for Q1 2025

On May 6, 2025, Jazz Pharmaceuticals plc (Nasdaq: JAZZ) reported its financial results for the first quarter of 2025, revealing significant commercial progress and adjusting its financial outlook for the year.

Financial Highlights

Total Revenues

In the first quarter, Jazz Pharmaceuticals achieved total revenues of $898 million, reflecting a steady demand for its key products. The strong performance was driven by revenue growth for products like Xywav and Epidiolex, which grew by 9% and 10%, respectively, compared to the previous year.

Product Performance

• - Xywav: The net product sales for Xywav reached $344.8 million, showing a 9% year-over-year increase. The company reported a notable addition of patients, with about 14,600 active patients receiving treatment as of the end of the quarter.
• - Epidiolex: Sales for Epidiolex climbed to $217.7 million, with the product being approved in over 35 countries outside of the U.S., hinting at its growing international acceptance.
• - Rylaze: In contrast, the net product sales for Rylaze dipped by 8% to $94.2 million, attributed largely to changes in pediatric treatment protocols impacting sales timing.

Strategic Moves

Jazz also made headlines with its acquisition of Chimerix, completed in April 2025. This acquisition brought dordaviprone, a promising treatment for a rare brain tumor, into Jazz's late-stage pipeline. The market is looking forward to an anticipated target data date for this candidate by August 18, 2025.

Pipeline Developments

Jazz Pharmaceuticals continues to demonstrate progress in its development pipeline:

• - They submitted a Supplemental New Drug Application (sNDA) for Zepzelca, targeting its use as maintenance therapy in treating extensive-stage small cell lung cancer.
• - The company is also expecting top-line data from the HERIZON-GEA-01 trial, evaluating their candidate zanidatamab, in the second half of 2025.

Financial Guidance for 2025

Jazz Pharmaceuticals reaffirmed its revenue guidance for 2025, targeting total revenues between $4.15 billion and $4.40 billion. This forecast indicates a robust 5% growth expectation at the midpoint, boosted by the performance of its diverse commercial portfolio.

Operational Insights

Despite revenue growth, the company reported a GAAP net loss of $92.6 million, resulting in a loss per share of $1.52. This loss, however, highlights the significant expenses related to certain antitrust litigation settlements impacting financial results.

Looking Ahead

With a validated commercial strategy and encouraging pipeline advancements, Jazz Pharmaceuticals looks poised to continue its growth trajectory throughout 2025. The company’s focus on delivering innovative therapeutic solutions positions it well to address unmet medical needs globally.

Jazz Pharmaceuticals remains committed to its mission of transforming the lives of patients through pioneering research and development, further detailed on their corporate website. As they proceed with key strategic initiatives, investors and stakeholders are eager to observe how Jazz navigates the challenges and opportunities that lie ahead.

• ---